Market Research Logo

Global Non-Hodgkin Lymphoma Therapeutics Market Analysis 2018 - Forecast to 2025

Global Non-Hodgkin Lymphoma Therapeutics Market Analysis 2018 - Forecast to 2025

Hoovers Research analysis is one of the most accurate studies performed using the combinational analytical tools. The report contains up to date financial data derived from varied research sources to present unique and reliable analysis. Assessment of major trends with potential impact on the market during the next eight years, including a deep dive analysis of market segmentation which comprises of sub markets, regional and country level analysis. The report provides a comprehensive outlook about the market share along with strategic recommendations based on the emerging segments.

This research report analyzes the global markets with in-depth insights. The market assessment is performed through standard and the tailored research methodology approach. The market overview offers in depth analysis at the regional and country level, for instance North America (U.S., Canada and Mexico), Europe (Germany, France, Italy, U.K., Spain and ROE), Asia-Pacific (China, Japan, India, Australia, South Korea and Rest of APAC), South America (Argentina, Brazil, Venezuela, Chile, and Peru) and Middle East & Africa (UAE, Saudi Arabia, Qatar, Iran, South Africa, and Rest of MEA). Annual estimations and forecasts are provided from the year 2014 to 2025 for each given segment and sub segments. Market data derived from the authenticated and reliable sources is subjected to validation from the industry experts. The report also analyzes the market by discussing market dynamics such as drivers, constraints, opportunities, threats, challenges and other market trends.

Competitive landscaping provides the recent activities performed by the active players in the market. Activities such as product launch, agreements, joint ventures, partnerships, acquisitions and mergers, and other activities.

This report provides:

  • Market Sizing estimations and forecasts across the given market segments
  • Identifying market dynamics (Drivers, Restraints, Opportunities, Threats, Challenges and Opportunities, )
  • Strategic recommendations in key business segments based on the market estimations
  • Regional and country level market analysis
  • Competitive landscaping of major market players
  • Company profiling covering the financials, recent activities and the future strategies


1 Introduction
1.1 Scope of the Report
1.2 Report Description
1.3 Research Methodology
1.4 Research Sources
1.4.1 Secondary Research
1.4.2 Primary Research
1.4.3 Assumptions
1.5 List of Abbreviations
2 Executive Summary
3 Market Analysis
3.1 Market Segmentation
3.2 Market Size Estimation
3.3 Market Drivers
3.4 Market Constraints
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Non-Hodgkin Lymphoma Therapeutics Market by Therapeutics
5.1 Introduction
5.2 Chemotherapy
5.2.1 Local Chemotherapy
5.2.2 Systemic Chemotherapy
5.3 Targeted Therapy
5.4 Radiation Therapy
5.4.1 Gamma-ray Therapy
5.4.2 X-ray Therapy
6 Non-Hodgkin Lymphoma Therapeutics Market by Cancer Type
6.1 Introduction
6.2 Schwannomas
6.3 Medulloblastoma
6.4 Glioma
6.4.1 Choroid Plexus Papilloma
6.4.2 Oligodendroglioma
6.4.3 Ependymoma
6.4.4 Astrocytoma
6.5 Meningioma
6.6 Pituitary Adenoma
7 Non-Hodgkin Lymphoma Therapeutics Market by Type
7.1 Introduction
7.2 Stem Cell Transplant
7.3 Immunotherapy
7.4 Surgery and Radiation Therapy
7.5 Chemotherapy
7.6 Targeted Therapy
7.7 Pharmacological
7.8 Other Types
8 Non-Hodgkin Lymphoma Therapeutics Market by Cell Type
8.1 Introduction
8.2 T-Cell Lymphomas
8.3 B-Cell Lymphomas
8.4 AIDS-Related Lymphomas
8.5 Mantel Cell Lymphoma
8.6 Blastic NK-Cell Lymphoma
8.7 Cutaneous T-Cell Lymphoma
8.8 T-Cell Leukemia
8.9 Burkitt’s lymphoma
8.10 Waldenstrom’s Macroglobulinemia
8.11 Follicular Lymphoma
9 Geographical Segmentation
9.1 North America
9.1.1 US
9.1.2 Canada
9.1.3 Mexico
9.2 Europe
9.2.1 Germany
9.2.2 France
9.2.3 Italy
9.2.4 UK
9.2.5 Spain
9.2.6 Rest of Europe
9.3 Asia Pacific
9.3.1 Japan
9.3.2 China
9.3.3 India
9.3.4 Australia
9.3.5 New Zealand
9.3.6 Rest of Asia Pacific
9.4 South America
9.4.1 Argentina
9.4.2 Brazil
9.4.3 Venezuela
9.4.4 Chile
9.4.5 Peru
9.5 Middle East & Africa
9.5.1 UAE
9.5.2 Saudi Arabia
9.5.3 Qatar
9.5.4 Iran
9.5.5 South Africa
9.5.6 Rest of MEA
10 Vendor Landscaping
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies
11 Company Profiles
11.1 Novartis
11.2 Merck
11.3 F. Hoffman La-Roche Ltd.
11.4 GlaxoSmithKline plc
11.5 Bristol Myers Squibb Co.
11.6 Bayer AG
11.7 Pfizer
11.8 CTI Biopharma
11.9 Kyowa Hakko Kirin
11.10 Pharmacyclics/Janssen Biotech
11.11 Millennium/Johnson-Johnson
11.12 Celgene
11.13 Spectrum Pharmaceuticals
11.14 Seattle Genetics
12 Appendix
13 Disclaimer
List of Tables
Table 1 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by Region, (2016-2025) ($MN)
Table 2 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by Therapeutics, (2016-2025) ($MN)
Table 3 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by Chemotherapy, (2016-2025) ($MN)
Table 4 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by Local Chemotherapy, (2016-2025) ($MN)
Table 5 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by Systemic Chemotherapy, (2016-2025) ($MN)
Table 6 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by Targeted Therapy, (2016-2025) ($MN)
Table 7 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by Radiation Therapy, (2016-2025) ($MN)
Table 8 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by Gamma-ray Therapy, (2016-2025) ($MN)
Table 9 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by X-ray Therapy, (2016-2025) ($MN)
Table 10 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by Cancer Type, (2016-2025) ($MN)
Table 11 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by Schwannomas, (2016-2025) ($MN)
Table 12 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by Medulloblastoma, (2016-2025) ($MN)
Table 13 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by Glioma, (2016-2025) ($MN)
Table 14 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by Choroid Plexus Papilloma, (2016-2025) ($MN)
Table 15 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by Oligodendroglioma, (2016-2025) ($MN)
Table 16 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by Ependymoma, (2016-2025) ($MN)
Table 17 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by Astrocytoma, (2016-2025) ($MN)
Table 18 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by Meningioma, (2016-2025) ($MN)
Table 19 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by Pituitary Adenoma, (2016-2025) ($MN)
Table 20 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by Type, (2016-2025) ($MN)
Table 21 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by Stem Cell Transplant, (2016-2025) ($MN)
Table 22 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by Immunotherapy, (2016-2025) ($MN)
Table 23 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by Surgery and Radiation Therapy, (2016-2025) ($MN)
Table 24 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by Chemotherapy, (2016-2025) ($MN)
Table 25 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by Targeted Therapy, (2016-2025) ($MN)
Table 26 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by Pharmacological, (2016-2025) ($MN)
Table 27 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by Other Types, (2016-2025) ($MN)
Table 28 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by Cell Type, (2016-2025) ($MN)
Table 29 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by T-Cell Lymphomas, (2016-2025) ($MN)
Table 30 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by B-Cell Lymphomas, (2016-2025) ($MN)
Table 31 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by AIDS-Related Lymphomas, (2016-2025) ($MN)
Table 32 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by Mantel Cell Lymphoma, (2016-2025) ($MN)
Table 33 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by Blastic NK-Cell Lymphoma, (2016-2025) ($MN)
Table 34 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by Cutaneous T-Cell Lymphoma, (2016-2025) ($MN)
Table 35 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by T-Cell Leukemia, (2016-2025) ($MN)
Table 36 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by Burkitt’s lymphoma, (2016-2025) ($MN)
Table 37 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by Waldenstrom’s Macroglobulinemia, (2016-2025) ($MN)
Table 38 Global Non-Hodgkin Lymphoma Therapeutics Market Analysis, by Follicular Lymphoma, (2016-2025) ($MN)
Note North America, Europe, Asia Pacific, South America and Middle East & Africa are represented in above manner.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report